Faron Pharmaceuticals Oy, a clinical-stage biopharmaceutical company, has released its Annual Report for the year 2023 and audited financial statements. The report is available in English and Finnish on the company's website. The company's lead asset, Bexmarilimab, is a novel anti-Clever-1 humanized antibody being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments. The BEXMAB study is an open-label Phase 1/2 clinical trial investigating Bexmarilimab in combination with standard of care (SoC) in aggressive hematological malignancies of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
Bexmarilimab is designed to overcome resistance to existing treatments and optimize clinical outcomes by targeting myeloid cell function and igniting the immune system. It binds to Clever-1, an immunosuppressive receptor found on macrophages, altering the tumor microenvironment and reprogramming macrophages from an immunosuppressive (M2) state to an immunostimulatory (M1) one, upregulating interferon production and priming the immune system to attack tumors and sensitizing cancer cells to standard of care.
Faron Pharmaceuticals' mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The company's focus is on tackling cancers via novel immunotherapies, with Bexmarilimab as its lead asset. The company's forward-looking statements reflect its current beliefs and assumptions and are based on information currently available to the Directors. However, the company cannot assure investors that actual results will be consistent with such forward-looking statements.
For more information, interested parties can contact the Investor and Media contacts provided in the announcement. The company's Certified Adviser on Nasdaq First North is Sisu Partners Oy. The announcement also includes contact information for the company's Nomad and Broker.